Tikomed’s ILB® in Oslo ALS Trial

Oslo University Hospital will conduct a phase 2 trial of Tikomed's ILB® for ALS, comparing it to Riluzole. The 116-patient study, starting in early 2026, will involve a double-blind phase followed by an open-label extension. Results are expected in 2028.



